Related Experiment Video
Updated: May 23, 2025
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Evaluating the Cardiometabolic Efficacy and Safety of Lipoprotein Lipase Pathway Targets in Combination With Approved
Eloi Gagnon1, Dipender Gill2, Dominique Chabot3
1Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Canada (E.G., S.T., B.J.A.).
Background:
Therapies targeting the LPL (lipoprotein lipase) pathway are under development for cardiometabolic disease. Insights into their efficacy-both alone and in combination with existing lipid-lowering therapies-modes of action, and safety of these agents are essential to inform clinical development. Using Mendelian randomization, we aimed to (1) evaluate efficacy, (2) explore shared mechanisms, (3) assess additive effects with approved lipid-lowering drugs, and (4) identify secondary indications and potential adverse effects.
Methods:
We selected triglyceride-lowering genetic variants located in the genes encoding ANGPTL3 (angiopoietin-like 3), ANGPTL4 (angiopoietin-like 4), APOC3 (apolipoprotein C3), and LPL and conducted drug target Mendelian randomization on primary outcomes including coronary artery disease and type 2 diabetes, and secondary outcomes, including apolipoprotein B, waist-to-hip ratio, body mass index, and 233 metabolic biomarkers. We conducted interaction Mendelian randomization analyses in 488 139 UK Biobank participants to test the effect of combination therapy targeting the LPL and LDLR (low-density lipoprotein receptor) pathways. Finally, we investigated potential secondary indications and adverse effects by leveraging genetic association data on 1204 disease end points.
Results:
Genetically predicted triglyceride lowering through the perturbation of LPL pathway activation targets ANGPTL4, APOC3, and LPL was associated with a lower risk of coronary artery disease and type 2 diabetes and lower apolipoprotein B. Genetically predicted triglyceride lowering through ANGPTL4 was associated with a lower waist-to-hip ratio, suggestive of a favorable body fat distribution. There was no evidence of a multiplicative interaction between genetically proxied perturbation of ANGPTL4, APOC3, and LPL and that of HMGCR (HMG-CoA reductase) and PCSK9 (proprotein convertase subtilisin/kexin type 9) on coronary artery disease and type 2 diabetes, consistent with additive effects. Finally, associations of genetically predicted LPL pathway targeting were supportive of the broad safety of these targets.
Conclusions:
Our findings provide genetic evidence supporting the efficacy and safety of LPL pathway activation therapies for the prevention of coronary artery disease and type 2 diabetes, alone or in combination with statins or PCSK9 inhibitors.
Insights
Lipoprotein lipase (LPL) pathway therapies show promise for preventing cardiovascular disease and type 2 diabetes. Genetic analysis supports their efficacy and safety, both alone and combined with statins or PCSK9 inhibitors.
Area of Science:
- Cardiovascular Genetics
- Metabolic Disease Research
- Pharmacogenomics
Background:
- Emerging therapies target the lipoprotein lipase (LPL) pathway for cardiometabolic diseases.
- Understanding the efficacy, mechanisms, and safety of these LPL-targeting agents is crucial for clinical development.
- This study investigates LPL pathway therapies alone and in combination with existing lipid-lowering treatments.
Purpose of the Study:
- Evaluate the efficacy of LPL pathway therapies in preventing cardiovascular disease and type 2 diabetes.
- Explore shared mechanisms and assess additive effects with approved lipid-lowering drugs.
- Identify potential secondary indications and adverse effects of LPL pathway modulation.
Main Methods:
- Utilized Mendelian randomization incorporating genetic variants in ANGPTL3, ANGPTL4, APOC3, and LPL.
- Assessed primary outcomes (coronary artery disease, type 2 diabetes) and secondary outcomes (lipids, body composition, metabolic biomarkers).
- Conducted interaction Mendelian randomization in UK Biobank participants and analyzed genetic associations for 1204 disease endpoints.
Main Results:
- Genetically predicted triglyceride lowering via ANGPTL4, APOC3, and LPL targets reduced coronary artery disease and type 2 diabetes risk, and lowered apolipoprotein B.
- ANGPTL4 perturbation was linked to reduced waist-to-hip ratio, indicating improved body fat distribution.
- No multiplicative interaction was observed between LPL pathway targets and HMGCR/PCSK9, suggesting additive effects; safety profiles were broadly supportive.
Conclusions:
- Genetic evidence supports the efficacy of LPL pathway activation therapies for preventing coronary artery disease and type 2 diabetes.
- These therapies demonstrate safety, both as monotherapy and in combination with statins or PCSK9 inhibitors.
- Findings support the clinical development of LPL pathway modulators for cardiometabolic disease management.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...